Follicular Lymphoma: Answers to Important Nursing Questions
November 2, 2021
November 2, 2022
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by the American Academy of CME, Inc.
Supported by an independent education grant from Epizyme.
- Nurses — 1.50 contact hours (1.35 pharmacotherapeutic contact hours)
All other healthcare professionals completing this course will be issued a statement of participation.
This activity is designed to meet the educational needs of oncology nurses, nurse practitioners and navigators engaged in the care of patients with follicular lymphoma.
Advances in the treatment of FL have led to the approval of two novel agents as well as updates to clinical practice guidelines. Oncology nursing professionals have unique and often long-standing relationships with their FL patients and are trusted sources of information and support. Those who care for patients with FL should be aware of treatment guideline changes and their impact on clinical practice. Recently approved novel medications are associated with unique toxicities that differ from standard chemotherapy and more familiar regimens. As the healthcare provider most likely to see and manage toxicities, oncology nursing professionals need education about these toxicities and their management in order to proactively mitigate potential issues and provide appropriate patient and caregiver education. Finally, the COVID-19 pandemic has impacted clinical practices in patients with FL and recommendations are updated as information becomes available. Oncology nurses need to be able to educate patients about risk-reduction practices and treatment approaches that minimize their risk of COVID-19 infection.
Upon completion of this activity, participants should be better able to:
- Compare the efficacy and safety of recently approved medications to those that are historically used to treat FL
- Describe features of adverse events associated with new classes of agents approved for FL while educating patients being treated with new agents about how to identify, monitor, and respond to adverse events
- Implement practices that reflect current recommendations to minimize the risk of COVID-19 infection in patients with FL while educating patients and caregivers about how to minimize their risk of COVID-19 infection
Amy Goodrich, CRNP
Johns Hopkins Kimmel Cancer Center
Joint Accreditation Statement
In support of improving patient care, American Academy of CME, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nursing Credit Designation
American Academy of CME, Inc., designates this enduring educational activity for 1.50 ANCC contact hours (1.35 pharmacotherapeutic contact hours).
Provider approved by the California Board of Registered Nursing. California BRN Provider # CEP16993
Disclosures of Conflicts of Interest
Amy Goodrich, CRNP
- Advisory Board for Scientific Information: AbbVie, AstraZeneca, Beigene, Pharmacyclics, SeaGen
John JD Juchniewicz, MCIS, CHCP, FACEHP, Natalie Kirkwood RN, BSN, JD, Wendy Gloffke, PhD and Paul Miniter, MS - No relevant financial relationships with any ineligible companies.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Complete the activity assessment (scoring at least 70%) and submit the evaluation form.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.
Disclosure of Unlabeled Use
American Academy of CME, Inc requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
There will be no discussion of non-FDA approved or investigational use of any product/device in this activity.
This activity is designed for educational purposes. The opinions expressed in this accredited continuing education activity are those of the faculty, and do not represent those of the Academy. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions please contact: email@example.com.